Skip to content

Net margin at other companies

NeoGenomics logo
NeoGenomicsNEO
-13.3%+2.4pp
Veracyte logo
VeracyteVCYT
16.2%+9.1pp
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-16.8%-7.3pp
Personalis, Inc. logo
Personalis, Inc.PSNL
-148.1%+154pp
Guardant Health logo
Guardant HealthGH
-40.1%-8.1pp
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-22.2%-9.5pp

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Calculated from Biodesix, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s net margin?
Biodesix, Inc. (BDSX) reported net margin of -33.3% in Q1 2026.
How has Biodesix, Inc.'s net margin changed year-over-year?
Biodesix, Inc.'s net margin increased by 38.7% year-over-year, from -54.3% to -33.3%.
What is the long-term trend for Biodesix, Inc.'s net margin?
Over 5 years (2020 to 2025), Biodesix, Inc.'s net margin has grown at a -22.6% compound annual growth rate (CAGR), from -143.7% to -39.8%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.